Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 5th World Congress on Control and Prevention of HIV/AIDS, STDs & STIs London, UK.

Day 2 :

Keynote Forum

Mandy J Hill

UT Health Science Center at Houston, USA

Keynote: Predictors of sexual scripts among young, sexually-active, substance-using African American women

Time : 10:05-10:45

OMICS International STD-HIV/AIDS 2017 International Conference Keynote Speaker Mandy J Hill photo

Mandy J Hill is a trained Clinical Researcher. She has advanced a prevention-based public health agenda within a clinical environment. Her academic portfolio to date has demonstrated feasibility of HIV prevention through formative intervention work that is designed to meet the people where they are, including the emergency department. Her current research agenda is to adapt efficacious interventions to varied settings where vulnerable populations at especially high risk for HIV infection can be accessed. She has published 22 peer reviewed manuscripts, 10 she first authored in diverse areas addressing health disparities among minority populations, coupled national and international presentations and extramural funding support from the CDC and the NIH through the American Psychological Association and Centers for AIDS Research, as well as industry sponsored research. In summary, her expertise includes randomized clinical trial development and implementation, and integrating public health-based prevention research into varied settings that include the emergency department.


Statement of the Problem: The HIV epidemic in the US continues to disproportionately affect the health of young, African American women. The focus here is on predictors of sexual scripts, which are roadmaps to sexual decision making. The objective is to examine life experiences, normative beliefs, and cultural predictors of sexual scripts that place young, sexuallyactive, substance-using, African American women (YSSAAW), a population with significant vulnerability to HIV, at even greater risk of becoming HIV positive.
Methodology & Theoretical Orientation: Face-to-face, tablet-assisted, semi-structured interviews were conducted with 30 YSSAAW in a private or public emergency department in Houston, TX, USA. Interviews were professionally transcribed,
then coded by a trained 3-member coding team. One interview was used to create the codebook. Codes were organized into primary themes during face-to-face meetings. Inter-coder reliability was assessed and confirmed using Cohen’s Kappa statistics, demonstrating a nearly perfect agreement between coders 1 and 2 (K=0.93).
Findings: Three primary themes were described as predictors of sexual scripts: emotional wounds, norms and decision making. Prevalent codes among YSSAAW within the emotional wounds theme included infidelity (43.33%) and parental dynamics (56.67%). Under the norms theme, we found 66.7% of YSSAAW discussed their communication norms and 30% disclosed cultural norms. Within the sexual decision making theme, we gained relevant information and implications on relationship longevity and having an STI history among 46.67% of the sample.
Conclusion & Significance: Primary predictors of high risk sex revealed sexual scripts that demonstrated gender-based power differentials; thereby, supporting utility of a theoretical framework that includes the Sexual Script Theory and the Theory of Gender and Power. The logic model illustrates how emotional wounds from life experiences (i.e., trauma, abuse, abandonment) and socially acceptable norms establishes the sexual script of YSSAAW; whereby, high risk sex is the most likely outcome relative to prevention strategies.


Keynote Forum

Sarah Joseph

Senior Scientist, UK

Keynote: Vaccination strategies to maximise Immune Responses using DNA, MVA and adjuvanted gp140

Time : 11:00-11:40

OMICS International STD-HIV/AIDS 2017 International Conference Keynote Speaker Sarah Joseph photo

Sarah Joseph has a background in the immunology of infectious diseases living and working in Africa on schistosomiasis, TB and malaria. She joined the MRC Clinical Trials Unit at UCL in 2008 as an Epidemiologist in HIV prevention, focusing on a range of Phase I/II HIV vaccine trials. In June 2017, she joined the International AIDS Vaccine Initiative.


We have been exploring vaccination strategies employing DNA, pox and adjuvanted envelope protein in an effort to optimize immunogenicity in the context of overall feasibility. We assessed the impact of combining MVA-C and GLA adjuvanted gp140 after DNA-C priming; giving them together or sequentially to healthy HIV-uninfected adults. We expected Env-specific antibodies in 100%, hypothesized that Env-specific CD4+ T-cells might induce functional antibodies and that combining vaccines, shortening the schedule by 8 weeks would not compromise safety or immunogenicity. 40 volunteers were recruited at 2 UK sites, given 3 IM doses of DNA plasmids encoding env and gag-pol-nef at weeks 0/4/8, then 2 doses of MVA IM (encoding env and gag-pol-nef) and 2 of recombinant CN54gp140 protein with GLA-AF; randomized to receive these during the same visit at weeks 16/20 (accelerated) or sequentially at weeks 16/20/24/28 (standard). Primary outcomes included ≥ grade 3 safety events and a four-fold difference in CN54gp140-specific binding IgG. 2 participants experienced ≥ grade 3 asymptomatic raised liver enzymes leading to discontinuation of vaccinations. 100% made CN54gp140 IgG, but combining vaccines did not significantly alter the response. Neutralization of a tier 1 pseudovirus was superior in the standard group, T-cell ELISPOT responses were CD4 and Env-dominant and comparable; 85% and 82.4% responded in the accelerated and standard groups, but poly-functional T-cells appeared less frequent in the accelerated group. Combining MVA and gp140/ GLA-AF shortened the schedule by 8 weeks without impacting the titer of gp140-specific antibodies. Neutralizing antibody responses were modest despite the induction of Env-specific CD4+ T-cells and inferior in the accelerated group. There was also a trend toward lower T-cell responses in the accelerated group, although it remains possible that the timing of vaccinations was not optimal. Results will be discussed in the context of other relevant trials.